Lupus in Men: The Underrecognized Cardiovascular Risk You May Not Know About

Systemic lupus erythematosus is widely understood to be a disease of women. The epidemiological data support this: SLE affects women roughly nine times more often than men, and the peak incidence in women occurs during the reproductive years, suggesting hormonal drivers. As a result, lupus in men is consistently underrecognized, underdiagnosed, and underresearched.

This demographic invisibility has a cost. When men do develop lupus, the disease tends to be more severe, diagnosed later, and associated with a cardiovascular risk profile that is substantially worse than in women with the same condition. A man with lupus carries a cardiovascular burden that most physicians, and most patients themselves, do not fully appreciate.

Understanding why lupus produces such profound cardiovascular risk in men, and what that means for long-term cardiac monitoring, requires a clear look at the immunological, metabolic, and pharmacological mechanisms at work.

What Is Systemic Lupus Erythematosus?

Systemic lupus erythematosus is a chronic autoimmune disease in which the immune system loses tolerance to self-antigens, particularly nuclear antigens such as double-stranded DNA (dsDNA) and various proteins associated with the cell nucleus. The immune system produces autoantibodies against these self-antigens, which form immune complexes that deposit in tissues throughout the body, triggering complement activation and sustained inflammatory damage.

The result is a disease of remarkable breadth. Lupus can affect the skin (malar rash, discoid lesions, photosensitivity), joints (symmetric polyarthritis), kidneys (lupus nephritis), nervous system (cerebritis, peripheral neuropathy), serous membranes (pleuritis, pericarditis), blood (hemolytic anemia, leukopenia, thrombocytopenia), and the heart and vasculature in multiple ways.

Lupus is classified as a relapsing-remitting disease for most patients, with periods of active disease (flares) separated by periods of relative quiescence. However, the vascular and cardiovascular damage associated with lupus is cumulative and does not necessarily follow the pattern of clinical flares. Subclinical atherosclerosis progresses even during clinical remission.

Why Lupus Affects Men Differently

The sex disparity in lupus reflects complex hormonal, genetic, and immunological differences between men and women. Estrogen generally promotes humoral (B-cell-mediated) immune responses, which is partly why women mount stronger autoimmune responses. Androgens, including testosterone, tend to have immunomodulatory and anti-inflammatory effects, which may explain why lupus is less common in men.

But when men do develop lupus, the biological picture is often more aggressive.

Multiple studies and meta-analyses have documented that men with SLE have higher rates of renal involvement (lupus nephritis), a more severe manifestation that carries significant risk of end-stage renal disease. Men also have higher rates of serositis, thrombocytopenia, and discoid skin disease. The LUMINA study, one of the largest multiethnic SLE cohorts, found that male sex was an independent predictor of renal damage accrual, a finding replicated in several subsequent analyses.

Damage accrual in SLE is measured using the SLICC/ACR Damage Index, which tracks irreversible organ damage from any cause over the disease course. Men with SLE accrue damage faster than women across multiple organ systems, including the cardiovascular system.

Accelerated Atherosclerosis in SLE

The most important cardiovascular phenomenon in SLE is accelerated atherosclerosis. Patients with lupus develop atherosclerotic plaque at a rate that is dramatically faster than age-matched individuals without the disease, and the risk is not fully explained by traditional cardiovascular risk factors alone.

The landmark Pittsburgh cohort study found that women with SLE aged 35 to 44 were over 50 times more likely to have a myocardial infarction than age-matched women in the Framingham Heart Study. While this dramatic figure has been refined in more recent studies, the directional finding is substantial: SLE dramatically accelerates cardiovascular aging.

For men, the baseline cardiovascular risk is already higher than for women of the same age. Layering lupus-associated accelerated atherosclerosis on top of this already elevated baseline creates a compounding risk profile that demands proactive management.

The Inflammatory Driver

The central driver of accelerated atherosclerosis in SLE is chronic vascular inflammation. Lupus produces sustained activation of the innate and adaptive immune systems, with persistent elevation of pro-inflammatory cytokines including interferon-alpha, IL-6, and TNF-alpha. These cytokines damage endothelial cells, promote expression of adhesion molecules that facilitate leukocyte trafficking into arterial walls, oxidize circulating LDL, and stimulate smooth muscle cell proliferation within plaques.

Neutrophil extracellular traps (NETs), which are webs of chromatin and antimicrobial proteins released by neutrophils during SLE flares, have been shown to directly damage endothelial cells and contribute to plaque formation. The lupus-specific inflammatory environment essentially accelerates every step of the atherogenic process.

Corticosteroid-Mediated Risk

Corticosteroids have been the pharmacological backbone of lupus management for decades. They are effective at suppressing lupus flares and controlling acute organ-threatening disease. They also carry a substantial cardiovascular cost with long-term use.

Long-term corticosteroid exposure promotes hypertension through mineralocorticoid effects, drives insulin resistance and frank diabetes, contributes to dyslipidemia (raising LDL and triglycerides while reducing HDL), promotes central adiposity, and accelerates atherosclerosis directly through effects on vascular smooth muscle and endothelium. Men with SLE who require sustained high-dose corticosteroid therapy for disease control carry a particularly elevated cardiovascular risk that requires proactive monitoring.

Lupus Nephritis and Cardiovascular Risk

Lupus nephritis, the renal manifestation of SLE that is disproportionately common in men, creates an independent cardiovascular risk pathway. The kidneys regulate blood pressure, fluid balance, and several aspects of lipid metabolism. When lupus damages the kidneys, the resulting chronic kidney disease amplifies cardiovascular risk through multiple mechanisms.

Chronic kidney disease is independently associated with accelerated atherosclerosis, endothelial dysfunction, left ventricular hypertrophy, arrhythmias, and sudden cardiac death. Men with both SLE and significant lupus nephritis carry additive cardiovascular risk from the autoimmune disease itself, the inflammatory burden, the treatments required, and the renal damage.

Additionally, proteinuria, the hallmark of active lupus nephritis, independently predicts cardiovascular events across multiple disease states. The mechanisms include loss of protective proteins in the urine, secondary dyslipidemia, and chronic activation of the renin-angiotensin-aldosterone system.

Specific Cardiac Manifestations of SLE in Men

Pericarditis

Pericarditis, inflammation of the pericardial sac surrounding the heart, is the most common cardiac manifestation of SLE overall, occurring in 15 to 40 percent of patients during the disease course. It typically presents with pleuritic chest pain (sharp, positional pain that worsens with inspiration and lying flat) and may be detected on electrocardiogram as diffuse ST elevation with PR depression.

In the majority of SLE patients, pericarditis is self-limited and responds to anti-inflammatory management. However, recurrent pericarditis and constrictive pericarditis are recognized complications that can substantially impair cardiac function. Your cardiologist may evaluate for signs of pericardial effusion or constriction if you have SLE and unexplained exertional symptoms.

Myocarditis

Myocarditis, inflammation of the myocardium itself, is less common than pericarditis in SLE but potentially more dangerous. Lupus myocarditis can present as unexplained heart failure, new-onset arrhythmias, or nonspecific symptoms such as fatigue and dyspnea. Cardiac biomarkers (troponin) may be elevated, and cardiac magnetic resonance imaging (MRI) has become the preferred diagnostic tool for detecting myocardial inflammation.

The prevalence of subclinical myocarditis in SLE, detected by cardiac MRI in patients without overt cardiac symptoms, appears higher than previously recognized. Whether subclinical myocarditis detected on imaging requires treatment modification is an active area of clinical investigation. Discuss with your cardiologist if you have SLE and unexplained exercise intolerance or palpitations.

Libman-Sacks Endocarditis

Libman-Sacks endocarditis is a noninfective form of endocarditis specifically associated with SLE and antiphospholipid antibody syndrome. It produces sterile vegetations on the cardiac valves, most commonly the mitral valve, that are composed of fibrin, inflammatory cells, and immune complexes rather than microorganisms.

These vegetations are typically small and may not cause significant valvular dysfunction, but they carry a risk of embolization, potentially causing stroke or other thromboembolic events. Antiphospholipid antibodies, which are found in approximately 30 to 40 percent of SLE patients, dramatically increase the risk of Libman-Sacks endocarditis and thromboembolism.

Men with SLE should discuss with their physicians whether antiphospholipid antibody testing is appropriate and, if positive, what cardiovascular monitoring is indicated.

Accelerated Coronary Artery Disease

Beyond the pericardium, myocardium, and valves, the coronary arteries themselves are affected by SLE-associated accelerated atherosclerosis. Men with SLE can present with acute coronary syndromes at unusually young ages, and the clinical presentation may be atypical, complicating recognition.

Coronary computed tomography angiography (CCTA) and coronary artery calcium (CAC) scoring have emerged as useful tools for quantifying subclinical coronary atherosclerosis in SLE patients who do not yet have overt symptoms. Your cardiologist may discuss the role of these assessments in your cardiovascular risk stratification.

Why Lupus in Men Is Diagnosed Late

Delayed diagnosis is a defining feature of male lupus and compounds the cardiovascular risk by extending the period of uncontrolled autoimmune activity.

The diagnostic delay in men with SLE has multiple drivers. Physician suspicion is lower because the disease is so strongly associated with women in the medical culture; many clinicians do not reflexively consider SLE in a male patient presenting with arthritis, fatigue, and rash. Referral patterns to rheumatology may be slower for men presenting with these symptoms.

Men with lupus may also have atypical presentations. Discoid lupus (the scarring skin manifestation) is proportionally more common in men and can present years before systemic involvement is recognized. A man with discoid lupus who has not yet developed systemic features may not be flagged for autoimmune evaluation.

Additionally, men tend to present to healthcare systems less frequently overall and may delay seeking evaluation for symptoms that are not acutely disabling. By the time diagnosis is established, the cumulative disease burden and vascular damage may already be significant.

Cardiovascular Monitoring for Men With Established SLE

For men who have already been diagnosed with SLE, proactive cardiovascular monitoring is a standard component of comprehensive care. The specific elements of monitoring vary by disease severity, organ involvement, and individual risk factors, and your rheumatologist and cardiologist together should guide this plan.

In general terms, the cardiovascular monitoring framework for men with SLE includes:

Blood pressure and renal function. Given the high rates of lupus nephritis in men, blood pressure monitoring and regular assessment of renal function are fundamental. Hypertension in SLE amplifies atherosclerosis risk and may signal active nephritis.

Lipid assessment. Fasting lipid panels are important at diagnosis and periodically thereafter, particularly when corticosteroid therapy is being used. Dyslipidemia in SLE is common and often requires management.

Glucose and HbA1c. Corticosteroid-related glucose dysregulation is common and can progress to frank diabetes without systematic monitoring.

Echocardiography. Echocardiography is the primary tool for evaluating pericardial, myocardial, and valvular abnormalities in SLE. Your cardiologist may recommend baseline echocardiography at diagnosis and repeat studies if new symptoms develop.

Antiphospholipid antibody evaluation. This testing has important implications for thromboembolism risk and the management of Libman-Sacks endocarditis.

Coronary risk stratification. For men with SLE and additional cardiovascular risk factors, your cardiologist may discuss whether coronary artery calcium scoring or other subclinical atherosclerosis assessment tools are appropriate for risk stratification.

The Intersection of Androgens and Lupus

An understudied but important dimension of male lupus is the potential role of androgen deficiency. Some data show that men with SLE have lower circulating testosterone levels than age-matched healthy men, possibly related to the inflammatory milieu or the direct effects of the autoimmune process on gonadal function.

Low testosterone is independently associated with elevated cardiovascular risk in men, including increased risk of coronary artery disease, metabolic syndrome, and all-cause mortality. Whether androgen deficiency in male SLE contributes to the excess cardiovascular risk seen in this population, and whether it should be evaluated and addressed, is an area where the evidence is currently limited. Discuss with your physician if you have symptoms consistent with testosterone deficiency alongside your SLE management.

Living With SLE as a Man: Advocacy and Self-Monitoring

Given the systemic underrecognition of lupus in men and the significant cardiovascular implications, men with SLE need to be informed and proactive participants in their own care.

Understanding your antinuclear antibody (ANA) pattern, your complement levels (C3, C4), and your anti-dsDNA antibody titers, and how these fluctuate with disease activity, helps you recognize when your disease may be flaring before symptoms become severe. Knowing your cardiovascular risk factor profile, including blood pressure, fasting lipids, and glucose, gives you the information to have meaningful conversations with both your rheumatologist and your cardiologist.

Advocating for cardiovascular evaluation if you have unexplained chest pain, shortness of breath, palpitations, or leg swelling is important because providers who are focused on rheumatological management may not immediately connect these symptoms to cardiac involvement. A cardiologist who has experience with autoimmune disease is the ideal partner for this monitoring.

Summary

Men with SLE represent a small proportion of all lupus patients but carry a disproportionately high burden of cardiovascular disease. Accelerated atherosclerosis, pericarditis, myocarditis, Libman-Sacks endocarditis, and coronary artery disease are all recognized cardiac manifestations of SLE, and they operate on top of the baseline cardiovascular risk that men carry. Delayed diagnosis, more severe renal involvement, corticosteroid burden, and chronic inflammation compound this risk.

If you are a man with SLE, your cardiac risk deserves the same systematic attention as your rheumatological management. The conversation with your cardiologist should not wait until you have symptoms.

Frequently Asked Questions

Q: How much does lupus increase heart attack risk in men specifically? A: The risk elevation from lupus-associated accelerated atherosclerosis is substantial, though precise figures vary by study design, disease severity, and cardiovascular risk factor burden. Men with SLE and additional risk factors such as hypertension, lupus nephritis, or antiphospholipid antibodies appear to face the highest cardiovascular risk. Discuss your individual risk profile with your cardiologist.

Q: Does having lupus mean I will get heart disease? A: Not necessarily. Cardiovascular risk in SLE exists on a spectrum determined by disease activity, organ involvement, treatment burden, and modifiable risk factors. Men with well-controlled SLE who do not have significant lupus nephritis, antiphospholipid antibodies, or prolonged high-dose corticosteroid exposure have a lower cardiovascular risk profile than those who do. Proactive monitoring and risk factor control substantially affect outcomes.

Q: What cardiac symptoms should a man with lupus not ignore? A: Chest pain (particularly sharp pain that varies with body position or breathing), unexplained shortness of breath, new palpitations or irregular heartbeat, and leg swelling deserve prompt evaluation in the context of SLE. These can reflect pericarditis, myocarditis, valvular disease, or arrhythmia. Do not attribute these symptoms to lupus flare without cardiac evaluation.

Q: Why is lupus so often missed in men? A: Physician awareness of lupus skews strongly toward women because the disease is nine times more common in women overall. Men with lupus may present with atypical patterns, and referral to rheumatology may be delayed. Men also tend to seek care less frequently and may not report symptoms until disease is more advanced. If you have persistent unexplained joint pain, fatigue, and skin changes, advocate for ANA testing.

Q: Does the treatment for lupus cause its own heart problems? A: Long-term corticosteroid therapy, which is commonly used in SLE management, is associated with hypertension, glucose dysregulation, dyslipidemia, and accelerated atherosclerosis. These risks are real and are factored into treatment decisions by your rheumatologist. Newer targeted therapies may carry a lower cardiovascular burden than corticosteroids, but all treatment discussions belong between you and your treating physicians.

The Signal Check is fifteen questions mapping the male cardiovascular risk pattern, including the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.